ARWR is expected to report earnings to rise 29.03% to -120 cents per share on August 06
Q2'26
Est.
$-1.20
Q1'26
Beat
by $0.11
Q4'25
Beat
by $0.10
Q3'25
Beat
by $0.20
Q2'25
Missed
by $0.40
The last earnings report on May 07 showed earnings per share of -93 cents, beating the estimate of -103 cents. With 2.75M shares outstanding, the current market capitalization sits at 10.47B.
A.I. Advisor
published General Information
General Information
a developer of novel drugs to treat intractable diseases
A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with AXON. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then AXON could also see price increases.
ARWR in downward trend: price dove below 50-day moving average on July 10, 2026
ARWR moved below its 50-day moving average on July 10, 2026 date and that indicates a change from an upward trend to a downward trend. In of 43 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ARWR moved out of overbought territory on July 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARWR as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ARWR turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARWR advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .
ARWR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 226 cases where ARWR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARWR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.036) is normal, around the industry mean (20.966). P/E Ratio (48.719) is within average values for comparable stocks, (37.802). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.511). ARWR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (16.611) is also within normal values, averaging (398.284).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARWR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
